Table 2.
Characteristic | n(%) or Mean ± SD | |
---|---|---|
Personal Characteristics
| ||
Race (n) | ||
Caucasian | 14 (100) | |
Marital status | ||
Married | 11 (79) | |
Occupational status | ||
Employed | 4 (21) | |
Not working (retired, disabled, not able to find a job) | 10 (79) | |
Age (yr) | 58.8 ± 6.7 | |
| ||
Disease and Treatment Characteristics
| ||
Time since breast cancer diagnosis (months) | 35 ± 20 | |
Self-Reported Lymph-Node Status (n) | ||
Negative | 8 (57) | |
Positive | 6 (43) | |
Cancer Treatment | ||
Mastectomy | 6 (43) | |
Lumpectomy | 8 (57) | |
Radiation therapy | 13 (93) | |
Chemotherapy | 9 (64) | |
HER2/neu receptor antibody | 2 (14) | |
AET | 14 (100) | |
Time (months) since AET initiation | 28.3 ± 17.9 | |
Type | ||
Aromatase Inhibitor | 12 (86) | |
Tamoxifen | 1 (7) | |
Unknown | 1 (7) | |
Adjustment of AET | 5 (36) | |
Reasons for AET adjustment | ||
Menopausal transition (eligible for tamoxifen to aromatase inhibitor conversion) | 2 (14) | |
Intolerable adverse effects | 2 (14) | |
No reason given | 1 (7) | |
Percentage of AET related symptoms rated 2 or higher | 44.6 ± 17.2 | |
Most bothersome symptoms as rated on the BCPT | ||
Symptom Scale | ||
General Aches | 2.9 ± 0.7 | |
Joint Pains | 2.9 ± 1.0 | |
Muscle Stiffness | 2.7 ± 1.1 | |
Lack of Interest in Sex | 2.5 ± 1.6 | |
Hot Flashes | 2.3 ± 0.9 |
Of note: Numbers may not sum to total due to rounding.